Industry News — Clinical Updates

FDA Announces Recall of Akorn Products

This afternoon, FDA issued a recall of various human products within expiry from Akorn as a result of the company’s ceasing operations. Because all operations and employees were terminated, the company cannot maintain a quality program to support or guarantee that the products will meet all intended specifications through the labeled shelf life of the product. Further distribution or use of any remaining product on the market should cease immediately. A full list of impacted products is available on the FDA’s website.

 If you have questions, please contact Allison Madson, vice president of health policy, at

(Published 4.26.23)